Revenue for FY2026 Q1 was 234.3 billion yen, with full-year guidance of 883.5 billion yen and progress of 26.5%. Growth driven by the pharmaceutical business, with contributions from key products such as Lenivima, Lequenbi, and Deebigo. Considering exchange rate impact and restructuring-related costs. Core operating profit of 24.7 billion yen, with a full-year target of 70.0 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4523-20260803-02.pdf","jir_short_summary":"Revenue for FY2026 Q1 was 234.3 billion yen, with full-year guidance of 883.5 billion yen and progress of 26.5%. Growth driven by the pharmaceutical business, with contributions from key products such as Lenivima, Lequenbi, and Deebigo. Considering exchange rate impact and restructuring-related costs. Core operating profit of 24.7 billion yen, with a full-year target of 70.0 billion yen.","jir_summary":"### Financial Performance Overview\nEisai reported FY2026 Q1 net sales of 23.43 billion yen (1Q actual, full-year forecast 88.35 billion yen, progress 26.5%). Growth driven by the pharmaceutical business, with contributions from flagship products Lenvim, Lekenbi, and Deebigo. Selling, general and administrative expenses and R&D costs increased, but core operating profit remained solid. Currency effects contributed to sales and profits to a degree. Certain severance-related costs associated with a business restructuring were partially recognized.\n\n### Outlook and Investor Impact\nFull-year FY2026 sales forecast of 883.5 billion yen, progress 26.5%, and core operating profit of 70.0 billion yen are anticipated. Steady growth in key product lines and progress of new development products are expected to support performance. However, ongoing currency fluctuations and continued increases in R&D investment may impact margins. Monitor quarterly trends and approvals\/sales developments of major development candidates going forward.","jir_financial_highlights":"Sales Revenue: 2,343 (Year-over-year \/ not disclosed (1Q actual))\nOperating Profit: 247 (Year-over-year \/ not disclosed)\nCore Operating Profit: 247 (Year-over-year \/ not disclosed)\nQuarterly Profit: 192 (Year-over-year \/ not disclosed)\nCash Flow: Operating cash flow 11 \/ Investing \u25b394 \/ Financing 261 (1Q actual)","jir_category":"","jir_hashtags":"#Eisai, #financial_summary, #JapaneseStocks","jir_key_figures":"Sales Revenue 2,343 (billion yen) \/ Progress 26.5%\nFull-year Forecast 8,835 (billion yen) \/ Sales share 100.0%\nCore Operating Profit 247 (billion yen) \/ Progress 35.3%","jir_meta_title":"\u3010Eisai\u3011 FY2026 Q1 Financial Results\uff5cSales 2,343 billion yen, Progress to 8,835 billion yen 26.5%","jir_meta_description":"FY2026 Q1 financial results overview for Eisai. Sales 2,343 billion yen, full-year forecast 8,835 billion yen, growth drivers in the pharmaceutical business, core operating profit trend, currency impact, and major development products.","jir_og_title":"Eisai: FY2026 Q1 Financial Results Overview","jir_og_description":"Eisai's Q1 results show sales of 2,343 billion yen with full-year guidance of 8,835 billion yen. Analyzes growth of core products and R&D investment.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q1\\\",\\\"FY2025 Q2\\\",\\\"FY2025 Q3\\\",\\\"FY2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales Revenue\\\",\\\"data\\\":[2027,1974,2199,2054]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q1\\\",\\\"FY2025 Q2\\\",\\\"FY2025 Q3\\\",\\\"FY2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Profit\\\",\\\"data\\\":[207,137,200,-103]}]}}\"}, {\"jir_chart_id\": \"core_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Core Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q1\\\",\\\"FY2025 Q2\\\",\\\"FY2025 Q3\\\",\\\"FY2025 Q4\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Core Operating Profit\\\",\\\"data\\\":[217,247,? ,?]}]}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Americas\\\",\\\"China\\\",\\\"EMEA\\\",\\\"EAGS\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Pharmaceuticals\\\",\\\"data\\\":[? , ?, ?, ?, ?]}]}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Full-year Guidance vs Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"1Q\\\",\\\"Full-year\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast vs Actual\\\",\\\"data\\\":[2343,8835]}]}}\"}]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-93452","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n